Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Exclusion Criteria

• •Erythrodermic, guttate, generalized pustular form of psoriasis
• •History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol
• •Congestive heart failure
• •History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
• •Concurrent malignancy or a history of malignancy as described in the protocol
• •History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)
• •Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug in the UK, Czech Republic, Germany, and France, and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 5 months following the last dose in France and within 10 weeks in all other countries
• •Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study